LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management
A Monday Morning Joe Online Educational Activity
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ, Radia DH, George TI, et al. Nat Med. 2021;27(12):2183-2191.
Efficacy and safety of midostaurin in advanced systemic mastocytosis.
Gotlib J, Kluin-Nelemans HC, George TI, et al. N Engl J Med. 2016;374(26):2530-2541.
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J, Reiter A, Radia DH, et al. Nat Med. 2021;27(12):2192-2199.
Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management.
Pardanani A. Am J Hematol. 2021;96(4):508-525.
NGS testing practices and molecular profile landscape of the KIT gene in systemic mastocytosis: real-world insights from selected European countries.
Lamontagne N, Cheloni S, Lima S, et al. Blood. 2022;140(suppl 1):2603-2604.
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J, Reiter A, Radia DH, et al. Nat Med. 2021;27(12):2192-2199.
Clinical Guidelines
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Arber DA, Orazi A, Hasserjian RP, et al. Blood. 2022;140(11):1200-1228.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.
Khoury JD, Solary E, Abla O, et al. Leukemia. 2022;36(7):1703-1719.
NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis.
National Comprehensive Cancer Network.
Patient Resources
The Mast Cell Disease Society, Inc. (TMS)
TMS is dedicated to providing multifaceted support to patients, families, and medical professionals in the community and to leading the advancement of knowledge and research in mast cell diseases through education, advocacy, and collaboration.
The European Competence Network on Mastocytosis (ECNM)
The goal of the ECNM is to improve disease-recognition, diagnosis, and therapy in patients with mastocytosis in Europe.
National Organization for Rare Disorders (NORD)
NORD is a patient advocacy organization committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management
A Monday Morning Joe Online Educational Activity
| Faculty: | Andrew Kuykendall, MD; Tracy I. George, MD |
| Release: | 10/02/2023 |
| Expiration: | 10/02/2024 |
